Photo from wikipedia
Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end‐organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for the… Click to show full abstract
Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end‐organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for the treatment of symptomatic nOH in adults. As the largest subpopulation of patients with nOH has a diagnosis of Parkinson disease (PD), the efficacy and tolerability of droxidopa in patients with PD and nOH were examined using integrated clinical trial data.
Keywords:
treatment;
parkinson disease;
droxidopa;
orthostatic hypotension;
neurogenic orthostatic
Journal Title: Movement Disorders Clinical Practice
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Movement Disorders Clinical Practice
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!